DepoMed Management Discusses Q2 2012 Results - Earnings Call Transcript

DepoMed (DEPO)

Q2 2012 Earnings Call

August 02, 2012 5:00 pm ET

Executives

August J. Moretti - Chief Financial Officer and Senior Vice President

James A. Schoeneck - Chief Executive Officer, President and Director

Jack Anders

Matthew M. Gosling - Senior Vice President and General Counsel

Analysts

Scott R. Henry - Roth Capital Partners, LLC, Research Division

Jason N. Butler - JMP Securities LLC, Research Division

Jason Napodano - Zacks Investment Research Inc.

James F. Molloy - ThinkEquity LLC, Research Division

Presentation

Operator

Good afternoon, and welcome to the DepoMed Reports Second Quarter Fiscal Year 2012 Financial Results. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to August Moretti, Chief Financial Officer of DepoMed. Please go ahead.

August J. Moretti

Thank you, operator. Good afternoon, and welcome to our second quarter financial results and business update conference call. With me today are Jim Schoeneck, President and CEO of DepoMed; Matt Gosling, Senior Vice President and General Counsel; Dr. Mike Sweeney, Chief Medical Officer; and Jack Anders, Senior Director of Finance.

Before we get started, I'd like to remind you that some matters discussed on this call contain forward-looking statements that involve risks and uncertainties, including those relating to the commercial launches of Gralise and Zipsor, the efforts of Santarus to commercial Glumetza, the submission of a new drug application for Serada, our projected revenue on expenses and the ability of DepoMed to support operations based on existing cash resources.

Actual results may differ materially from the results predicted, and recorded results should not be considered an indication of future performance. These and other risk factors are more fully discussed in our annual report on Form 10-K and our quarterly report on Form 10-Q for the first quarter of this year. And they will be fully discussed in the quarterly report on Form 10-Q that we will file with the SEC in the next day or so. In each case, under the caption Risk Factors.

If you liked this article you might like

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

Depomed Focuses on Flagship Drug Rather Than M&A: CEO